Search

Your search keyword '"Pierantozzi, M."' showing total 441 results
Start Over Author "Pierantozzi, M."
441 results on '"Pierantozzi, M."'

4. The Retinal Posterior Pole in Early Parkinson’s Disease: A Fundus Perimetry and SD-OCT Study

Author

Cesareo M, Di Marco E, Giannini C, Di Marino M, Aiello F, Pisani A, Pierantozzi M, Mercuri NB, Nucci C, and Mancino R

Subjects
parkinson's disease, optical coherence tomography, retina, dopamine, alpha-synuclein, Ophthalmology, RE1-994
Abstract

Massimo Cesareo,1 Ernesto Di Marco,1 Clarissa Giannini,1 Matteo Di Marino,1 Francesco Aiello,1 Antonio Pisani,2 Mariangela Pierantozzi,3 Nicola Biagio Mercuri,4,5 Carlo Nucci,1 Raffaele Mancino1 1Ophthalmology Unit, Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy; 2Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; 3Parkinson’s Center, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; 4Neurology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; 5Fondazione Santa Lucia I.R.C.C.S, Rome, ItalyCorrespondence: Massimo Cesareo; Ernesto Di MarcoOphthalmology Unit, Department of Experimental Medicine University of Rome “Tor Vergata”, via Montpellier, Rome, 100133, ItalyTel/Fax +39 0620902973Email massimo.cesareo@uniroma2.it; Ernesto2601@hotmail.itPurpose: To assess the structure and function of the retinal posterior pole in patients with early Parkinson’s disease (PD) and to identify possible biomarkers correlated with clinical features.Patients and Methods: A cross-sectional case-control study of 21 patients with PD and 22 age-matched healthy controls (HC) was conducted. All subjects underwent full ophthalmological examinations, fundus perimetry (FP) and spectral domain-OCT (SD-OCT) of the entire retinal posterior pole and peripapillary retinal nerve fiber layer (pRNFL).Results: We analyzed 41 eyes from 21 patients (14 males and 7 females) with early PD (Hoehn and Yahr scale (H&Y) equal to or less than stage 2) and 41 eyes from 22 HC (12 males and 10 females). We found no significant difference in the pRNFL thickness between patients with PD and HC. The statistical analysis of the SD-OCT posterior pole area, consisting of 64 values for each retinal layer, revealed a decrease in the outer nuclear layer (ONL) thickness in patients with PD (p < 0.0001). On the contrary, a significant increase in the thickness of the outer plexiform layer (OPL) (p < 0.0001) and of the retinal pigmented epithelium (RPE) (p= 0.002) compared to healthy controls was detected. Other retinal layers showed no significant statistical differences. The differential light sensitivity (DLS) values measured by FP were significantly lower in patients than the healthy controls (15 [13– 16.2] vs 17.95 [16.08– 18.96] p< 0.0001).Conclusion: Our results showed that DLS and retinal structure differed in the posterior pole between patients with early PD and controls. Thickening of the OPL may represent accumulation of α-synuclein in the OPL of patients with PD.Keywords: Parkinson’s disease, optical coherence tomography, retina, dopamine, alpha-synuclein

Published
2021

8. Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis

Author

Singh, B, Lant, S, Cividini, S, Cattrall, J, Goodwin, L, Benjamin, L, Michael, B, Khawaja, A, Matos, A, Alkeridy, W, Pilotto, A, Lahiri, D, Rawlinson, R, Mhlanga, S, Lopez, E, Sargent, B, Somasundaran, A, Tamborska, A, Webb, G, Younas, K, Al Sami, Y, Babu, H, Banks, T, Cavallieri, F, Cohen, M, Davies, E, Dhar, S, Modol, A, Farooq, H, Harte, J, Hey, S, Joseph, A, Karthikappallil, D, Kassahun, D, Lipunga, G, Mason, R, Minton, T, Mond, G, Poxon, J, Rabas, S, Soothill, G, Zedde, M, Yenkoyan, K, Brew, B, Contini, E, Cysique, L, Zhang, X, Maggi, P, van Pesch, V, Lechien, J, Saussez, S, Heyse, A, Brito Ferreira, M, Soares, C, Elicer, I, Eugenin-Von Bernhardi, L, Reyes, W, Yin, R, Azab, M, Abd-Allah, F, Elkady, A, Escalard, S, Corvol, J, Delorme, C, Tattevin, P, Bigaut, K, Lorenz, N, Hornuss, D, Hosp, J, Rieg, S, Wagner, D, Knier, B, Lingor, P, Winkler, A, Sharifi-Razavi, A, Moein, S, Seyed Alinaghi, S, Jamali Moghadam Siahkali, S, Morassi, M, Padovani, A, Giunta, M, Libri, I, Beretta, S, Ravaglia, S, Foschi, M, Calabresi, P, Primiano, G, Servidei, S, Mercuri, N, Liguori, C, Pierantozzi, M, Sarmati, L, Boso, F, Garazzino, S, Mariotto, S, Patrick, K, Costache, O, Pincherle, A, Klok, F, Meza, R, Cabreira, V, Valdoleiros, S, Oliveira, V, Kaimovsky, I, Guekht, A, Koh, J, Diaz, E, Barrios-Lopez, J, Guijarro-Castro, C, Beltran-Corbellini, A, Martinez-Poles, J, Diezma-Martin, A, Morales-Casado, M, Garcia, S, Breville, G, Coen, M, Uginet, M, Bernard-Valnet, R, Pasquier, R, Kaya, Y, Abdelnour, L, Rice, C, Morrison, H, Defres, S, Huda, S, Enright, N, Hassell, J, D'Anna, L, Benger, M, Sztriha, L, Raith, E, Chinthapalli, K, Nortley, R, Paterson, R, Chandratheva, A, Werring, D, Dervisevic, S, Harkness, K, Pinto, A, Jillella, D, Beach, S, Gunasekaran, K, Ferreira Da Silva, I, Nalleballe, K, Santoro, J, Scullen, T, Kahn, L, Kim, C, Thakur, K, Jain, R, Umapathi, T, Nicholson, T, Sejvar, J, Hodel, E, Smith, C, Solomon, T, Singh B., Lant S., Cividini S., Cattrall J. W. S., Goodwin L. C., Benjamin L., Michael B. D., Khawaja A., Matos A. D. M. B., Alkeridy W., Pilotto A., Lahiri D., Rawlinson R., Mhlanga S., Lopez E. C., Sargent B. F., Somasundaran A., Tamborska A., Webb G., Younas K., Al Sami Y., Babu H., Banks T., Cavallieri F., Cohen M., Davies E., Dhar S., Modol A. F., Farooq H., Harte J., Hey S., Joseph A., Karthikappallil D., Kassahun D., Lipunga G., Mason R., Minton T., Mond G., Poxon J., Rabas S., Soothill G., Zedde M., Yenkoyan K., Brew B., Contini E., Cysique L., Zhang X., Maggi P., van Pesch V., Lechien J., Saussez S., Heyse A., Brito Ferreira M. L., Soares C. N., Elicer I., Eugenin-Von Bernhardi L., Reyes W. N., Yin R., Azab M. A., Abd-Allah F., Elkady A., Escalard S., Corvol J. -C., Delorme C., Tattevin P., Bigaut K., Lorenz N., Hornuss D., Hosp J., Rieg S., Wagner D., Knier B., Lingor P., Winkler A. S., Sharifi-Razavi A., Moein S. T., Seyed Alinaghi S. A., Jamali Moghadam Siahkali S., Morassi M., Padovani A., Giunta M., Libri I., Beretta S., Ravaglia S., Foschi M., Calabresi P., Primiano G., Servidei S., Mercuri N. B., Liguori C., Pierantozzi M., Sarmati L., Boso F., Garazzino S., Mariotto S., Patrick K. N., Costache O., Pincherle A., Klok F. A., Meza R., Cabreira V., Valdoleiros S. R., Oliveira V., Kaimovsky I., Guekht A., Koh J., Diaz E. F., Barrios-Lopez J. M., Guijarro-Castro C., Beltran-Corbellini A., Martinez-Poles J., Diezma-Martin A. M., Morales-Casado M. I., Garcia S. G., Breville G., Coen M., Uginet M., Bernard-Valnet R., Pasquier R. D., Kaya Y., Abdelnour L. H., Rice C., Morrison H., Defres S., Huda S., Enright N., Hassell J., D'Anna L., Benger M., Sztriha L., Raith E., Chinthapalli K., Nortley R., Paterson R., Chandratheva A., Werring D. J., Dervisevic S., Harkness K., Pinto A., Jillella D., Beach S., Gunasekaran K., Ferreira Da Silva I. R., Nalleballe K., Santoro J., Scullen T., Kahn L., Kim C. Y., Thakur K. T., Jain R., Umapathi T., Nicholson T. R., Sejvar J. J., Hodel E. M., Smith C. T., Solomon T., Singh, B, Lant, S, Cividini, S, Cattrall, J, Goodwin, L, Benjamin, L, Michael, B, Khawaja, A, Matos, A, Alkeridy, W, Pilotto, A, Lahiri, D, Rawlinson, R, Mhlanga, S, Lopez, E, Sargent, B, Somasundaran, A, Tamborska, A, Webb, G, Younas, K, Al Sami, Y, Babu, H, Banks, T, Cavallieri, F, Cohen, M, Davies, E, Dhar, S, Modol, A, Farooq, H, Harte, J, Hey, S, Joseph, A, Karthikappallil, D, Kassahun, D, Lipunga, G, Mason, R, Minton, T, Mond, G, Poxon, J, Rabas, S, Soothill, G, Zedde, M, Yenkoyan, K, Brew, B, Contini, E, Cysique, L, Zhang, X, Maggi, P, van Pesch, V, Lechien, J, Saussez, S, Heyse, A, Brito Ferreira, M, Soares, C, Elicer, I, Eugenin-Von Bernhardi, L, Reyes, W, Yin, R, Azab, M, Abd-Allah, F, Elkady, A, Escalard, S, Corvol, J, Delorme, C, Tattevin, P, Bigaut, K, Lorenz, N, Hornuss, D, Hosp, J, Rieg, S, Wagner, D, Knier, B, Lingor, P, Winkler, A, Sharifi-Razavi, A, Moein, S, Seyed Alinaghi, S, Jamali Moghadam Siahkali, S, Morassi, M, Padovani, A, Giunta, M, Libri, I, Beretta, S, Ravaglia, S, Foschi, M, Calabresi, P, Primiano, G, Servidei, S, Mercuri, N, Liguori, C, Pierantozzi, M, Sarmati, L, Boso, F, Garazzino, S, Mariotto, S, Patrick, K, Costache, O, Pincherle, A, Klok, F, Meza, R, Cabreira, V, Valdoleiros, S, Oliveira, V, Kaimovsky, I, Guekht, A, Koh, J, Diaz, E, Barrios-Lopez, J, Guijarro-Castro, C, Beltran-Corbellini, A, Martinez-Poles, J, Diezma-Martin, A, Morales-Casado, M, Garcia, S, Breville, G, Coen, M, Uginet, M, Bernard-Valnet, R, Pasquier, R, Kaya, Y, Abdelnour, L, Rice, C, Morrison, H, Defres, S, Huda, S, Enright, N, Hassell, J, D'Anna, L, Benger, M, Sztriha, L, Raith, E, Chinthapalli, K, Nortley, R, Paterson, R, Chandratheva, A, Werring, D, Dervisevic, S, Harkness, K, Pinto, A, Jillella, D, Beach, S, Gunasekaran, K, Ferreira Da Silva, I, Nalleballe, K, Santoro, J, Scullen, T, Kahn, L, Kim, C, Thakur, K, Jain, R, Umapathi, T, Nicholson, T, Sejvar, J, Hodel, E, Smith, C, Solomon, T, Singh B., Lant S., Cividini S., Cattrall J. W. S., Goodwin L. C., Benjamin L., Michael B. D., Khawaja A., Matos A. D. M. B., Alkeridy W., Pilotto A., Lahiri D., Rawlinson R., Mhlanga S., Lopez E. C., Sargent B. F., Somasundaran A., Tamborska A., Webb G., Younas K., Al Sami Y., Babu H., Banks T., Cavallieri F., Cohen M., Davies E., Dhar S., Modol A. F., Farooq H., Harte J., Hey S., Joseph A., Karthikappallil D., Kassahun D., Lipunga G., Mason R., Minton T., Mond G., Poxon J., Rabas S., Soothill G., Zedde M., Yenkoyan K., Brew B., Contini E., Cysique L., Zhang X., Maggi P., van Pesch V., Lechien J., Saussez S., Heyse A., Brito Ferreira M. L., Soares C. N., Elicer I., Eugenin-Von Bernhardi L., Reyes W. N., Yin R., Azab M. A., Abd-Allah F., Elkady A., Escalard S., Corvol J. -C., Delorme C., Tattevin P., Bigaut K., Lorenz N., Hornuss D., Hosp J., Rieg S., Wagner D., Knier B., Lingor P., Winkler A. S., Sharifi-Razavi A., Moein S. T., Seyed Alinaghi S. A., Jamali Moghadam Siahkali S., Morassi M., Padovani A., Giunta M., Libri I., Beretta S., Ravaglia S., Foschi M., Calabresi P., Primiano G., Servidei S., Mercuri N. B., Liguori C., Pierantozzi M., Sarmati L., Boso F., Garazzino S., Mariotto S., Patrick K. N., Costache O., Pincherle A., Klok F. A., Meza R., Cabreira V., Valdoleiros S. R., Oliveira V., Kaimovsky I., Guekht A., Koh J., Diaz E. F., Barrios-Lopez J. M., Guijarro-Castro C., Beltran-Corbellini A., Martinez-Poles J., Diezma-Martin A. M., Morales-Casado M. I., Garcia S. G., Breville G., Coen M., Uginet M., Bernard-Valnet R., Pasquier R. D., Kaya Y., Abdelnour L. H., Rice C., Morrison H., Defres S., Huda S., Enright N., Hassell J., D'Anna L., Benger M., Sztriha L., Raith E., Chinthapalli K., Nortley R., Paterson R., Chandratheva A., Werring D. J., Dervisevic S., Harkness K., Pinto A., Jillella D., Beach S., Gunasekaran K., Ferreira Da Silva I. R., Nalleballe K., Santoro J., Scullen T., Kahn L., Kim C. Y., Thakur K. T., Jain R., Umapathi T., Nicholson T. R., Sejvar J. J., Hodel E. M., Smith C. T., and Solomon T.

Abstract

Background Neurological COVID-19 disease has been reported widely, but published studies often lack information on neurological outcomes and prognostic risk factors. We aimed to describe the spectrum of neurological disease in hospitalised COVID-19 patients; characterise clinical outcomes; and investigate factors associated with a poor outcome. Methods We conducted an individual patient data (IPD) meta-analysis of hospitalised patients with neurological COVID-19 disease, using standard case definitions. We invited authors of studies from the first pandemic wave, plus clinicians in the Global COVID-Neuro Network with unpublished data, to contribute. We analysed features associated with poor outcome (moderate to severe disability or death, 3 to 6 on the modified Rankin Scale) using multivariable models. Results We included 83 studies (31 unpublished) providing IPD for 1979 patients with COVID-19 and acute new-onset neurological disease. Encephalopathy (978 [49%] patients) and cerebrovascular events (506 [26%]) were the most common diagnoses. Respiratory and systemic symptoms preceded neurological features in 93% of patients; one third developed neurological disease after hospital admission. A poor outcome was more common in patients with cerebrovascular events (76% [95% CI 67–82]), than encephalopathy (54% [42–65]). Intensive care use was high (38% [35–41]) overall, and also greater in the cerebrovascular patients. In the cerebrovascular, but not encephalopathic patients, risk factors for poor outcome included breathlessness on admission and elevated D-dimer. Overall, 30-day mortality was 30% [27–32]. The hazard of death was comparatively lower for patients in the WHO European region. Interpretation Neurological COVID-19 disease poses a considerable burden in terms of disease outcomes and use of hospital resources from prolonged intensive care and inpatient admission; preliminary data suggest these may differ according to WHO regions and country income levels. The dif

Published
2022

13. Comparison of different diagnostic methods for the detection of Enteromyxum leei (Myxozoa) in farmed gilthead sea bream (Sparus aurata)

Author

Gustinelli, A., Caffara, M., Magri, A., Pierantozzi, M., and Fioravanti, M.

Abstract

Enteromyxum leei is an enteric Myxozoan parasite causing the so-called “razor blade syndrome” in gilthead sea bream (Sparus aurata), a chronic condition characterized by a progressive weight loss up to emaciation in adult fish. Currently no treatments are found to be effective against this parasite, but a recent experimental study showed promising results using a functional feed for mitigating enteromyxosis (Palenzuela et al., 2020. Dis. Aquat. Org., 138, 111–120). During a field trial aimed to confirm the efficacy of this functional feed in an Italian sea bream facility where enteromyxosis was already known to be present, different methods for the detection of E. leei were compared to establish the more reliable diagnostic test also in relation to a non-lethal approach.

Published
2022
Full Text
View/download PDF

14. Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis

Author

Singh, B., Lant, S., Cividini, S., Cattrall, J.W.S., Goodwin, L.C., Benjamin, L., Michael, B.D., Khawaja, A., Matos, A.D.B., Alkeridy, W., Pilotto, A., Lahiri, D., Rawlinson, R., Mhlanga, S., Lopez, E.C., Sargent, B.F., Somasundaran, A., Tamborska, A., Webb, G., Younas, K., Sami, Y. al, Babu, H., Banks, T., Cavallieri, F., Cohen, M., Davies, E., Dhar, S., Modol, A.F., Farooq, H., Harte, J., Hey, S., Joseph, A., Karthikappallil, D., Kassahun, D., Lipunga, G., Mason, R., Minton, T., Mond, G., Poxon, J., Rabas, S., Soothill, G., Zedde, M., Yenkoyan, K., Brew, B., Contini, E., Cysique, L., Zhang, X., Maggi, P., Pesch, V. van, Lechien, J., Saussez, S., Heyse, A., Ferreira, M.L.B., Soares, C.N., Elicer, I., Eugenin-von Bernhardi, L., Reyes, W.N., Yin, R., Azab, M.A., Abd-Allah, F., Elkady, A., Escalard, S., Corvol, J.C., Delorme, C., Tattevin, P., Bigaut, K., Lorenz, N., Hornuss, D., Hosp, J., Rieg, S., Wagner, D., Knier, B., Lingor, P., Winkler, A.S., Sharifi-Razavi, A., Moein, S.T., SeyedAlinaghi, S., JamaliMoghadamSiahkali, S., Morassi, M., Padovani, A., Giunta, M., Libri, I., Beretta, S., Ravaglia, S., Foschi, M., Calabresi, P., Primiano, G., Servidei, S., Mercuri, N.B., Liguori, C., Pierantozzi, M., Sarmati, L., Boso, F., Garazzino, S., Mariotto, S., Patrick, K.N., Costache, O., Pincherle, A., Klok, F.A., Meza, R., Cabreira, V., Valdoleiros, S.R., Oliveira, V., Kaimovsky, I., Guekht, A., Koh, J., Diaz, E.F., Barrios-Lopez, J.M., Guijarro-Castro, C., Beltran-Corbellini, A., Martinez-Poles, J., Diezma-Martin, A.M., Morales-Casado, M.I., Garcia, S.G., Breville, G., Coen, M., Uginet, M., Bernard-Valnet, R., Pasquier, R. du, Kaya, Y., Abdelnour, L.H., Rice, C., Morrison, H., Defres, S., Huda, S., Enright, N., Hassell, J., D'Anna, L., Benger, M., Sztriha, L., Raith, E., Chinthapalli, K., Nortley, R., Paterson, R., Chandratheva, A., Werring, D.J., Dervisevic, S., Harkness, K., Pinto, A., Jillella, D., Beach, S., Gunasekaran, K., Silva, I.R.F. da, Nalleballe, K., Santoro, J., Scullen, T., Kahn, L., Kim, C.Y., Thakur, K.T., Jain, R., Umapathi, T., Nicholson, T.R., Sejvar, J.J., Hodel, E.M., Smith, C.T., Solomon, T., Brain Infect Global COVID-Neuro Ne, University of Liverpool, Fondation Ophtalmologique Adolphe de Rothschild [Paris], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pontchaillou [Rennes], ARN régulateurs bactériens et médecine (BRM), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Les Hôpitaux Universitaires de Strasbourg (HUS), The study was funded by the UK Medical Research Council’s Global Effort on COVID-19 Programme (MR/V033441/1) (https://mrc.ukri.org/), UK National Institute for Health Research (NIHR)- funded Global Health Research Group on Acute Brain Infections (17/63/110) (https://www.nihr.ac.uk/), and the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections (NIHR200907), at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford (Grant Nos. IS-HPU-1112-10117 and NIHR200907). These grants were awarded to TS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
General Science & Technology, [SDV]Life Sciences [q-bio], Autonomic dysfunction, PROVISIONAL CASE DEFINITIONS, MESH: Hospitalization, MESH: Prognosis, MESH: Stroke, MESH: Risk Factors, Risk Factors, MESH: COVID-19, Humans, Multidisciplinary, Science & Technology, Hospitalization, Prognosis, COVID-19, Stroke, MESH: Humans, Metaanalysis, Hospitals, Brain Infections Global COVID-Neuro Network Study Group, Multidisciplinary Sciences, Medical risk factors, Settore MED/26 - NEUROLOGIA, Cerebrospinal fluid, Encephalitis, Science & Technology - Other Topics, Dementia
Abstract

Background Neurological COVID-19 disease has been reported widely, but published studies often lack information on neurological outcomes and prognostic risk factors. We aimed to describe the spectrum of neurological disease in hospitalised COVID-19 patients; characterise clinical outcomes; and investigate factors associated with a poor outcome. Methods We conducted an individual patient data (IPD) meta-analysis of hospitalised patients with neurological COVID-19 disease, using standard case definitions. We invited authors of studies from the first pandemic wave, plus clinicians in the Global COVID-Neuro Network with unpublished data, to contribute. We analysed features associated with poor outcome (moderate to severe disability or death, 3 to 6 on the modified Rankin Scale) using multivariable models. Results We included 83 studies (31 unpublished) providing IPD for 1979 patients with COVID-19 and acute new-onset neurological disease. Encephalopathy (978 [49%] patients) and cerebrovascular events (506 [26%]) were the most common diagnoses. Respiratory and systemic symptoms preceded neurological features in 93% of patients; one third developed neurological disease after hospital admission. A poor outcome was more common in patients with cerebrovascular events (76% [95% CI 67–82]), than encephalopathy (54% [42–65]). Intensive care use was high (38% [35–41]) overall, and also greater in the cerebrovascular patients. In the cerebrovascular, but not encephalopathic patients, risk factors for poor outcome included breathlessness on admission and elevated D-dimer. Overall, 30-day mortality was 30% [27–32]. The hazard of death was comparatively lower for patients in the WHO European region. Interpretation Neurological COVID-19 disease poses a considerable burden in terms of disease outcomes and use of hospital resources from prolonged intensive care and inpatient admission; preliminary data suggest these may differ according to WHO regions and country income levels. The different risk factors for encephalopathy and stroke suggest different disease mechanisms which may be amenable to intervention, especially in those who develop neurological symptoms after hospital admission.

Published
2022

16. Depressive symptoms in Parkinson’s disease and in non-neurological medical illnesses

Author

Assogna F, Fagioli S, Cravello L, Meco G, Pierantozzi M, Stefani A, Imperiale F, Caltagirone C, Pontieri FE, and Spalletta G

Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Francesca Assogna,1 Sabrina Fagioli,1 Luca Cravello,1 Giuseppe Meco,2 Mariangela Pierantozzi,3 Alessandro Stefani,3 Francesca Imperiale,2 Carlo Caltagirone,1,3 Francesco E Pontieri,4 Gianfranco Spalletta11I.R.C.C.S. Santa Lucia Foundation, Rome, Italy; 2Department of Neurology and Psychiatry (Parkinson’s Centre) and Research Centre of Social Diseases (CIMS), University “Sapienza”, Rome, Italy; 3Department of Neuroscience, University “Tor Vergata”, Rome, Italy; 4Department of Neuroscience, Mental Health and Sensory Systems, University “Sapienza”, Movement Disorder Unit, Sant’Andrea Hospital, Rome, ItalyBackground: Patients with neurological and non-neurological medical illnesses very often complain of depressive symptoms that are associated with cognitive and functional impairments. We compared the profile of depressive symptoms in Parkinson’s disease (PD) patients with that of control subjects (CS) suffering from non-neurological medical illnesses.Methods: One-hundred PD patients and 100 CS were submitted to a structured clinical interview for identification of major depressive disorder (MDD) and minor depressive disorder (MIND), according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR), criteria. The Hamilton Depression Rating Scale (HDRS) and the Beck Depression Inventory (BDI) were also administered to measure depression severity.Results: When considering the whole groups, there were no differences in depressive symptom frequency between PD and CS apart from worthlessness/guilt, and changes in appetite reduced rates in PD. Further, total scores and psychic and somatic subscores of HDRS and BDI did not differ between PD and CS. After we separated PD and CS in those with MDD, MIND, and no depression (NODEP), comparing total scores and psychic/somatic subscores of HDRS and BDI, we found increased total depression severity in NODEP PD and reduced severity of the psychic symptoms of depression in MDD PD, with no differences in MIND. However, the severity of individual symptom frequency of depression was not different between PD and CS in MDD, MIND, and NODEP groups.Conclusion: Although MDD and MIND phenomenology in PD may be very similar to that of CS with non-neurological medical illnesses, neurological symptoms of PD may worsen (or confound) depression severity in patients with no formal/structured DSM-IV-TR, diagnosis of depressive mood disorders. Thus, a thorough assessment of depression in PD should take into consideration the different impacts of neurological manifestations on MDD, MIND, and NODEP.Keywords: Parkinson’s disease, neuropsychiatry, depression, nonmotor symptoms

Published
2013

47. Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up

Author

Sensi, M., Cossu, G., Mancini, F., Pilleri, M., Zibetti, M., Modugno, N., Quatrale, R., Tamma, F., Antonini, A., Aguggia, M., Amboni, M., Arca, R., Bartolomei, L., Bonetto, N., Calandra-Buonaura, G., Bove, F., Calandrella, D., Canesi, M., Cannas, A., Capecci, M., Caputo, E., Ceravolo, M. G., Ceravolo, R., Cerrone, G., Coletti Moja, M., Comi, C., Cortelli, P., D'Antonio, P., Dematteis, F., Di Lazzaro, V., Eleopra, R., Fabbrini, G., Fichera, M., Grassi, E., Guido, M., Gusmaroli, G., Latorre, A., Malaguti, M. C., Marano, M., Marano, P., Marconi, R., Mazzucchi, S., Meco, G., Minafra, B., Morgante, F., Pacchetti, C., Pierantozzi, M., Pontieri, F. E., Riboldazzi, G., Ricchi, V., Ricchieri, G., Rinaldo, S., Rispoli, V., Rossi, S., Rubino, A., Russo, A., Saddi, M. V., Stefani, A., Simoni, S., Solla, P., Tambasco, N., Tamburin, S., Tessitore, A., Torre, E., Ulivelli, M., Vita M., Gi, Volonté, M. A., on behalf of the, ITALIAN LEVODOPA CARBIDOPA INTESTINAL GEL WORKING GROUP, Sensi, M., Cossu, G., Mancini, F., Pilleri, M., Zibetti, M., Modugno, N., Quatrale, R., Tamma, F., Antonini, A., Aguggia, M., Amboni, M., Arca, R., Bartolomei, L., Bonetto, N., Calandra-Buonaura, G., Bove, F., Calandrella, D., Canesi, M., Cannas, A., Capecci, M., Caputo, E., Ceravolo, M. G., Ceravolo, R., Cerrone, G., Coletti Moja, M., Comi, C., Cortelli, P., D'Antonio, P., Dematteis, F., Di Lazzaro, V., Eleopra, R., Fabbrini, G., Fichera, M., Grassi, E., Guido, M., Gusmaroli, G., Latorre, A., Malaguti, M. C., Marano, M., Marano, P., Marconi, R., Mazzucchi, S., Meco, G., Minafra, B., Morgante, F., Pacchetti, C., Pierantozzi, M., Pontieri, F. E., Riboldazzi, G., Ricchi, V., Ricchieri, G., Rinaldo, S., Rispoli, V., Rossi, S., Rubino, A., Russo, A., Saddi, M. V., Stefani, A., Simoni, S., Solla, P., Tambasco, N., Tamburin, S., Tessitore, A., Torre, E., Ulivelli, M., Vita, M. G., Volonte, M. A., Sensi, Mariachiara, Cossu, Giovanni, Mancini, Francesca, Pilleri, Manuela, Zibetti, Maurizio, Modugno, Nicola, Quatrale, Rocco, Tamma, Filippo, Antonini, Angelo, Italian Levodopa Carbidopa Intestinal Gel Working Group [.., Calandra-Buonaura, Giovanna, Cortelli, Pietro, and ]

Subjects
Male, 0301 basic medicine, Pediatrics, Neurology, Parkinson's disease, Longitudinal Studie, Pharmacology, Antiparkinson Agents, Levodopa, 0302 clinical medicine, Retrospective Studie, Weight loss, Drug Combination, levodopa-carbidopa intestinal gel infusion, neuropathy, parkinson's disease, withdrawal, Longitudinal Studies, Gel, Carbidopa, Parkinson Disease, Health Survey, Intestine, Substance Withdrawal Syndrome, Intestines, Drug Combinations, Italy, Antiparkinson Agent, Withdrawal, Disease Progression, Female, Settore MED/26 - Neurologia, medicine.symptom, Human, medicine.drug, medicine.medical_specialty, Levodopa-carbidopa intestinal gel infusion, Neuropathy, Geriatrics and Gerontology, Neurology (clinical), 03 medical and health sciences, medicine, Humans, Adverse effect, Retrospective Studies, business.industry, Retrospective cohort study, Gels, Health Surveys, medicine.disease, Comorbidity, Discontinuation, 030104 developmental biology, business, 030217 neurology & neurosurgery
Abstract

Objectives To report the results of a national survey aimed at quantifying the current level of diffusion of Levodopa/carbidopa intestinal gel (LCIG) in Italy. Methods Sixty Parkinson's Disease (PD) specialists in Italy were invited to complete a survey covering issues on clinical and practical aspects of LCIG therapy. Results Clinical features of 905 patients were collected retrospectively. The majority of centres reported the use of a multidisciplinary team, biochemistry testing, neurophysiological and neuropsychological tests before and after treatment, in addition to caregivers' training and patient's follow as outpatients. Most centres (60%) used internal guidelines for patient selection. The overall rate of adverse events was 55.1%. Weight loss, chronic polyneuropathy and stoma infection were the most frequently reported. 40% of centres used replacement therapy with Vitamin B12 and Folic acid from the start of LCIG and continued this for the duration of treatment. The rate of discontinuation was of 25.7% overall, with 9.5% of cases occurring in the first year. The main causes of withdrawal were device-related complications, disease progression (comorbidity, severe dementia) and caregiver and/or patient dissatisfaction. Conclusions In Italy LCIG infusion is managed in a uniform manner at a clinical, practical and organizational level even though the selection criteria are not standardized through the country. The high percentage of patients remaining on treatment in the short- and long-term follow-up confirms effectiveness of treatment, careful follow-up, and appropriate patient and caregivers training.

Published
2017

49. SLE for the carbon dioxide +trans-1,3,3,3-tetrafluoropropene

Author

Di Nicola G., Cacciatore I., Pierantozzi M., and Arteconi A.

Subjects
Engineering (General). Civil engineering (General), TA1-2040
Abstract

A built experimental set-up was employed for the estimation of the solid-liquid equilibria of alternative refrigerants systems. The behavior of carbon dioxide + 1,3,3,3-tetrafluoropropene (CO2 + R1234ze(E)) was measured down to temperatures of 160.0 K. The results obtained for the mixtures were interpreted by means of the Schröder equation.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results